医師と製薬業界: 贈り物はただただ贈りものなのか?
1McGill University, Montreal, Quebec, Canada. cxwz@musica.mcgill.ca
JAMA
|January 27, 2000
まとめ
贈与やスポンサー教育を含む,製薬会社との医師の相互作用は,処方習慣や専門的な行動に影響します. 医学部から始まるこれらの関係は,政策と教育的な介入を正当化します.
科学分野:
- 医療倫理 医療倫理について
- 医薬品のマーケティング
- 医師の行動 医者の行動
背景:
- 医者が製薬業界の代表と接触することは一般的であり,かなりの金銭的促進を伴う.
- 慣行には,贈り物,食事,旅行補助金,スポンサーによる指導,シンポジウムなどが含まれる.
研究 の 目的:
- 医師と製薬業界の関係に関する範囲と態度を評価する.
- これらの相互作用が医師の知識,態度,行動に与える影響を評価する.
主な方法:
- MEDLINE検索 (1994年~現在) を実施し,参考リストをレビューしました.
- インターネットのデータベースを検索し,主要情報提供者をインタビューした.
- 538件の対象研究のうち29件の検索研究を分析し,分析デザインの質を優先した.
主要な成果:
- 医師と製薬会社の代表者との交流は,月平均4回で,医学部で始まり,一般的に承認されています.
- 相互作用は,処方箋のリクエストと処方箋の変更と相関しています.
- スポンサーによる継続医療教育 (CME) と旅行資金は,スポンサー薬の処方率を高め,非合理的な処方に関連しています.
結論:
- 医師と産業の相互作用は,処方箋と専門的行動に大きく影響します.
- これらの関係には,政策や教育改革を通じてさらなる注意が必要である.
関連する概念動画
Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
Drug Abuse and Addiction: Pharmacological Phenomena
1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Biopharmaceutics and Pharmacokinetics: Overview
5.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
5.1K
Drug Control Governance: Regulatory Bodies and Their Impact
674
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
674
Drug Administration and Therapy Phases: Overview
2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
236
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
236


